Flex Pharma launches ALS phase 2 study with FLX-787 in US

Flex Pharma has initiated a Phase 2 randomized, controlled, double-blinded, parallel design trial in the US.

The COMMEND trial will evaluate FLX-787, the Company’s co-activator of TRPA1 and TRPV1, in patients with motor neuron disease (MND), focused on ALS, who suffer from painful, debilitating cramps.

The FDA has granted FLX-787 Fast Track designation for the treatment of severe muscle cramps associated with ALS. The Company expects to report topline results from this study in the middle of 2018. The Company also intends to initiate a Phase 2 clinical trial in CMT this quarter.

“Muscle cramps can have a severe impact on functional performance and quality of life for patients with motor neuron diseases like ALS,” indicated lead investigator Dr. Björn Oskarsson of the Mayo Clinic in Jacksonville, Florida. “Neurologists are often confronted with a situation where the patient experiences symptoms, and current treatments are either ineffective or have potentially limiting side effects. Flex Pharma’s FLX-787 may provide a better approach to this challenging problem.”

“The Fast Track designation for FLX-787 is a validation by FDA that cramps are a severe, unmet medical need in ALS,” commented Dr. William McVicar, Flex Pharma President and CEO. “While physicians treating ALS patients have come to understand how great an impact severe cramping – and the pain that attends it – can have on the lives of ALS patients, the lack of safe and effective and treatments has provided little impetus to focus on the problem. We are working hard to change this with FLX-787.”

Add Comment

Click here to post a comment